Marjorie Taylor Greene disclosed on Wednesday that she traveled to Mexico for stem cell therapy, citing high U.S. healthcare costs and lack of regulatory approval as primary reasons. The former Congresswoman stated in a post on X that she does not have health insurance and highlighted that rising costs are driving Americans to seek medical treatments abroad. Greene noted that the specific therapy she received is not approved by the U.S. Food and Drug Administration, which contributed to her decision to go overseas.

Greene provided specific figures to illustrate the financial burden of healthcare in the United States. She stated that a family of four can spend up to $27,000 annually on health insurance, with additional deductibles ranging from $7,000 to $10,000. "Health insurance is absurdly expensive," Greene said, emphasizing the financial strain on households.

Her comments align with new data from Gallup and West Health indicating that healthcare affordability in the U.S. has fallen to its lowest level in five years. The survey revealed that only 49% of U.S. adults could consistently afford quality healthcare and prescription drugs in 2025, a decline from 61% in 2022. The data further showed that approximately 2.8 million more Americans struggled to afford healthcare in 2025 compared to the previous year.

The Gallup survey identified specific demographics facing the most significant affordability challenges, including young adults, women, Black and Hispanic Americans, and individuals with chronic or mental health conditions. Concern regarding future costs is also prevalent, with 51% of Americans expressing worry about paying for healthcare services and 42% concerned about affording prescription drugs.

Costs are projected to continue rising for insured individuals as well. Employer health benefit costs are expected to increase 6.7% in 2026 to at least $18,500 per employee, marking the largest annual increase in 15 years. Large employers anticipate raising deductibles, copays, and out-of-pocket costs, while prescription drug benefit costs are projected to rise around 9% in 2026.

Former President Donald Trump criticized previous US administrations for their handling of the semiconductor industry, stating that the failure to implement tariffs allowed foreign nations to dominate manufacturing. In a post on Truth Social, Trump argued that the technology the world relies on was invented in America, but "stupid presidents" allowed the industry to move to places like Taiwan.

Trump highlighted the historical significance of American innovation, referencing the "Intel Inside" era. He asserted that past leaders took the economy for granted and neglected to protect industries with trade policies such as tariffs.

The post linked to the specific statement on his social media platform, where he reiterated his stance on bringing manufacturing back to the United States. Trump claimed that his victory in the recent election signaled a clear mandate to rebuild the domestic semiconductor sector.

Key Statements

• Origin of Technology: Trump stated that the foundational technology was invented in America.
• Policy Criticism: He blamed the loss of factories on the absence of protective tariffs.
• Future Goal: Trump emphasized the necessity of restoring the American semiconductor industry.